Intersection between Obesity, Dietary Selenium, and Statin Therapy in Brazil

Area of Science:

• Nutrition Science
• Public Health
• Biochemistry

Background:

• Obesity is a major global health issue, particularly in Brazil, affecting about 25% of the population.
• Obesity results from overnutrition and undernourishment, leading to adipose tissue dysfunction, dyslipidemia, and micronutrient deficiencies.
• Statins, used by 60% of obese patients for dyslipidemia, can cause myopathies in ~10% of users.

Purpose of the Study:

• To examine the impact of obesity and selenium deficiency on statin side effects in Brazil.
• To investigate the intersection of nutritional status, obesity, and statin treatment in the Brazilian context.
• To highlight the public health implications of these combined factors.

Main Methods:

• Literature review focusing on obesity, selenium deficiency, and statin-induced myopathies.
• Analysis of the biochemical pathways affected by statins, including cholesterol and selenoprotein synthesis.
• Examination of the prevalence of selenium deficiency in the Brazilian population.

Main Results:

• Statins may impair selenoprotein synthesis, especially with selenium deficiency, potentially causing myopathies.
• The Brazilian population's susceptibility to selenium deficiency may increase their risk of statin-related side effects.
• Obesity exacerbates nutritional deficiencies, creating a vulnerable group for adverse drug reactions.

Conclusions:

• The combination of obesity, selenium deficiency, and statin use poses a significant health risk in Brazil.
• Understanding these interactions is crucial for developing targeted nutritional and therapeutic strategies.
• Further research is needed to elucidate the precise mechanisms and clinical implications for the Brazilian population.